3-(Aminomethyl)-2,4-dimethylpentane hydrochloride | 1797941-32-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-(Aminomethyl)-2,4-dimethylpentane hydrochloride
• 英文别名: 3-methyl-2-propan-2-ylbutan-1-amine;hydrochloride
• CAS: 1797941-32-2
• 化学式: C8H20ClN
• mdl: MFCD28012196
• 分子量: 165.7
• InChiKey: MXIWXEIPSLJVAH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.08
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  1

文献信息

• Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
  申请人：——

  公开号：US20030166644A1

  公开（公告）日：2003-09-04

  Use of compounds to inhibit hormone-sensitive lipase, pharmaceutical compositions comprising the compounds, methods of treatment employing these compounds and compositions, and novel compounds. The present compounds are inhibitors of hormone-sensitive lipase and may be useful in the treatment and/or prevention of medical disorders where a decreased activity of hormone-sensitive lipase is desirable.

  使用化合物抑制激素敏感性脂肪酶，包括这些化合物的药物组合物，使用这些化合物和组合物的治疗方法，以及新化合物。目前的化合物是激素敏感性脂肪酶的抑制剂，可能在治疗和/或预防需要降低激素敏感性脂肪酶活性的医学疾病中有用。
• Process for the preparation of N,N' -carbonylbislactams
  申请人：——

  公开号：US20010044532A1

  公开（公告）日：2001-11-22

  The invention relates to a process for the preparation of N,N′-carbonylbislactams by reaction of phosgene with at least one lactam which is characterized in that the tertiary amine is chosen from the group consisting of non-nucleophilic aliphatic tertiary amines. N,N′-Carbonylbislactams of high purity are thus obtained with good yields, both in the laboratory and on the industrial scale.

  该发明涉及一种通过光气与至少一种内酰胺反应制备N,N′-羰基双内酰胺的方法，其特点在于所选择的三级胺来自由非亲核脂肪族三级胺组成的群。因此，在实验室和工业规模上均可获得高纯度的N,N′-羰基双内酰胺，并且产率良好。
• [EN] 8 - SULFO - IMIDAZOTETRAZIN- 4 - ONE COMPOUNDS AND THEIR USE AS ANTICANCER DRUG<br/>[FR] COMPOSÉS 8-SULFO-IMIDAZOTÉTRAZIN-4-ONE ET LEUR UTILISATION EN TANT QUE MÉDICAMENT ANTICANCÉREUX
  申请人：PHARMINOX LTD

  公开号：WO2012085501A1

  公开（公告）日：2012-06-28

  Compounds of formula (I) and pharmaceutically acceptable salts, hydrates or solvates thereof are provided (I) wherein B, X, and Y are as defined herein. The compounds are of use in methods of regulating cell proliferation, inhibiting cell cycle progression, and/or promoting apoptosis, and in the treatment of proliferative disorders.

  提供具有化学式（I）及其药用可接受的盐、水合物或溶剂化合物（I）的其中B、X和Y的定义如本文所述。这些化合物在调节细胞增殖、抑制细胞周期进展和/或促进凋亡的方法中有用，并用于治疗增生性疾病。
• METHOD FOR PREPARING A SULFONIMIDE COMPOUND AND SALTS THEREOF
  申请人：RHODIA OPERATIONS

  公开号：US20150203449A1

  公开（公告）日：2015-07-23

  The present invention relates to a method for preparing an aqueous sulfonimide compound of the formula (Rf 1 —SO 2 ) (Rf 2 —SO 2 )NH, wherein Rf 1 et Rf 2 are independently selected from the group comprising: a fluorine atom and groups having 1 to 10 carbon atoms selected from the perfluoroalkyl, fluoroalkyl, fluoroalkenyl and fluoroallyl groups, from a mixture M1 including (Rf 1 —SO 2 )(Rf 2 —SO 2 )NH, Rf 1 SO 2 H and/or Rf 2 SO 2 H, Rf 1 SO 2 NH 2 and/or Rf 2 SO 2 NH 2 , characterized in that said method includes an oxidation step of said mixture M1 using an oxidizing agent in order to obtain a mixture M2 including (Rf 1 —SO 2 )(Rf 2 —SO 2 )NH, Rf 1 SO 3 H and/or Rf 2 SO 3 H, and Rf 1 SO 2 NH 2 and/or Rf 2 SO 2 NH 2 .

  本发明涉及一种制备以下公式的含硫酰亚胺化合物水溶液的方法： (Rf1—SO2)(Rf2—SO2)NH，其中Rf1和Rf2独立地选自包括氟原子和1至10个碳原子的全氟烷基、氟烷基、氟烯基和氟烯基的组中，从一个包括 (Rf1—SO2)(Rf2—SO2)NH，Rf1SO2H和/或Rf2SO2H，Rf1SO2NH2和/或Rf2SO2NH2的混合物M1中，其特征在于，所述方法包括使用氧化剂对所述混合物M1进行氧化步骤，以获得包括 (Rf1—SO2)(Rf2—SO2)NH，Rf1SO3H和/或Rf2SO3H，以及Rf1SO2NH2和/或Rf2SO2NH2的混合物M2。
• [EN] INHIBITORS OF HDME<br/>[FR] INHIBITEURS DE HDME
  申请人：EPITHERAPEUTICS APS

  公开号：WO2012007007A1

  公开（公告）日：2012-01-19

  The present invention relates to compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic disregulation is involved in the pathogenesis, such as e.g. cancer. The present invention also relates to pharmaceutical compositions comprising said compounds and to the use of such compounds as a medicament.

  本发明涉及能够调节组蛋白去甲基化酶（HDMEs）活性的化合物，这些化合物对于预防和/或治疗基因组失调参与发病机制的疾病，如癌症等，具有用处。本发明还涉及包含所述化合物的药物组合物以及将这些化合物用作药物的用途。